Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of povorcitinib in moderate to severe hidradenitis suppurativa
jRCT2051230048Phase 3Completed
- Sponsor
- Incyte
- Start
- Aug 2023
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of povorcitinib in hidradenitis suppurativa (HS) (3 arms), sponsored by Incyte. Primary endpoint: HiSCR at Week 12. Started Aug 2023; status: completed.
02
Drugs
povorcitinib
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on jRCT2051230048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051230048.